Vir enlists Covid-19 antibody rival for cancer, infectious disease discovery work

Vir — Bob Nelsen and George Scangos’ infectious disease startup — is going into immuno-oncology.

Enlisting Harbour BioMed as a partner, Vir will tap the trans-Pacific biotech’s platform tech to generate a suite of antibodies aimed at treating both cancer and infectious diseases. The goal is to “exploit similar underlying immune mechanisms that likely play a critical role” in both areas, said Harbour CEO Jingsong Wang.